文献类型：期刊文献

英文题名：Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study

作者：Zhao, Xiaoli[1];Wang, Bole[1];Zhang, Yihe[2];Li, Pengqing[3];Liang, Xuexue[1];Gong, Qinli[1];Tian, Ling[3];Qin, Tianyan[3];Chen, Xuelian[3];Li, Zhenglin[2];Nie, Peng[2];Zhang, Yanshan[2];Ye, Yancheng[3]

第一作者：赵雪灵;赵贤兰;赵小玲

通信作者：Zhang, YS[1];Ye, YC[2]

机构：[1]Gansu Univ Chinese Med, Dept Publ Hlth, Lanzhou, Gansu, Peoples R China;[2]Gansu Wuwei Tumor Hosp, Dept Radiotherapy, Wuwei, Gansu, Peoples R China;[3]Gansu Wuwei Tumor Hosp, Follow Up Off, Wuwei, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Wuwei Tumor Hosp, Dept Radiotherapy, Wuwei, Gansu, Peoples R China;[2]corresponding author), Gansu Wuwei Tumor Hosp, Follow Up Off, Wuwei, Gansu, Peoples R China.

年份：2026

卷号：16

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;Scopus(收录号：2-s2.0-105046437430);WOS:【SCI-EXPANDED(收录号:WOS:001818977800001)】；

基金：The author(s) declared that financial support was received for this work and/or its publication. Funding for this study was provided by the Chief Scientist Project of Gansu Province (Grant No. 26RCKH001), the Key Research and Development Project of Gansu Province (Grant No. 26YFFH001), and the Graduate Innovation Fund of Gansu Provincial Department of Education (Grant No. 2026CXZX-937).

语种：英文

外文关键词：adverse reactions; carbon ions; efficacy; non-small cell lung cancer; radiotherapy

摘要：Objective To evaluate the clinical efficacy and adverse reactions of carbon ion radiotherapy (CIRT) for stage III non-small cell lung cancer (NSCLC), and to analyze factors influencing patient prognosis.Methods A retrospective analysis was conducted on the clinical data and follow-up records of 82 patients diagnosed with stage III NSCLC who underwent CIRT between March 2020 and March 2024. The total CIRT dose administered ranged from 48 to 78 Gy (relative biological effectiveness, RBE), with a median follow-up duration of 31.5 months. The Kaplan-Meier method was used to calculate overall survival (OS), progression-free survival (PFS), and local control (LRC) rates. The Cox regression model was employed to analyze prognostic factors, and Firth's Cox model was utilized for subgroup analysis. Adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Results Among the 82 patients, the 1-year OS, PFS, and LRC rates were 85.4%, 79.8%, and 95.3%, respectively; the 2-year OS, PFS, and LRC rates were 65.9%, 50.8%, and 82.9%. The median PFS was 26 months. Grade 1 radiation pneumonitis occurred in 5 patients (6.1%); grade 1 radiation esophagitis was observed in 36 patients (43.9%)with 3 patients (3.7%) experiencing grade 2; grade 1 radiation dermatitis was noted in 2 cases (2.4%), grade 2 in 1 case (1.2%), and grade 3 in 1 case (1.2%). Grade 3 or higher adverse reactions were primarily hematologic, with grade 3 lymphopenia being the most common (29 cases, 35.37%). Multivariate analysis revealed that CIRT combined with immunotherapy was an independent favorable factor for improving OS (P = 0.025). The results of subgroup analysis also indicate that the survival benefits of combined treatment are highly consistent across different subgroups.Conclusion The use of carbon ion therapy for stage III NSCLC can achieve significant survival benefits, and the adverse reactions are manageable. CIRT combined with immunotherapy is an independent factor for improving patient OS; however, further prospective studies are still needed to validate this association and determine the optimal treatment strategy.